Altre lingue Vivos Inc.

Azioni

RDGL

US92858K2042

Tempo differito OTC Markets Altri mercati azionari 19:51:47 23/05/2024			Variaz. 5gg	Var. 1 gen.
0,1461 ^USD	-2,70%		-20,64%	+102,07%

09/05	Vivos Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
18/03	Vivos Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Vivos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Vivos Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation	20/12
Vivos Inc. Announces Radiogel(TM) Precision Radionuclide Therapy(TM) Receives FDA Breakthrough Device Designation	20/12
Vivos Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	06/11
Vivos : Quarterly Progress Report - Form 8-K	11/10/23
Vivos Inc. Announces Certification of Three New IsoPet® Precision Radionuclide Therapy Regional Clinics	07/08/23
Vivos Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	04/08/23
VIVOS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	04/05/23
Vivos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	04/05/23
VIVOS INC : Unregistered Sale of Equity Securities (form 8-K)	02/05/23
VIVOS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	01/03/23
Vivos Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/03/23
Vivos Inc. Auditor Raises 'Going Concern' Doubt	01/03/23
Vivos Inc Files a New Patent on Alternate Particles for Precision Radionuclide Therapy	11/01/23
Vivos Inc Files A New Patent on Alternate Particles for Precision Radionuclide Therapy	11/01/23
Vivos Inc Files a New Patent on Precision Radionuclide Therapy Support System Equipment	03/01/23
Vivos Inc. Files New Patent on Precision Radionuclide Therapy Support System Equipment	03/01/23
VIVOS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	19/10/22
Vivos Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	19/10/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Vivos Inc.

Azioni

RDGL

US92858K2042

Altre lingue

Filtri